Table 3.

Risk of mortality associated with benzodiazepine initiation versus non-initiation in high dimensional propensity score matched sensitivity and subgroup analyses

Analysis	Benzodiazepine initiators					Benzodiazepine non-initiators				Hazard ratio (95% CI)
	No of patients	No of Events	Person years	Incidence/1000 person years		No of patients	No of events	Person years	Incidence/1000 person years
Follow-up duration (months):
12	1 252 988	7671	986 396	7.8		1 252 988	6552	855 316	7.7	1.04 (1.01 to 1.08)
48	1 252 988	13 532	2 241 015	6.0		1 252 988	10 299	1 696 159	6.1	1.05 (1.02 to 1.07)
Patient age (years):
<65	1 156 209	2160	504 932	4.3		1 156 209	1843	462 811	4.0	1.09 (1.02 to 1.15)
≥65	92 273	2599	39 716	65.4		92 273	2708	36 438	74.3	0.89 (0.85 to 0.94)
Drug duration of action:
Short acting	1 011 732	4973	440 142	11.3		1 011 732	4370	403 954	10.8	1.06 (1.02 to 1.10)
Long acting	412 976	869	181 483	4.8		412 976	1341	165 450	8.1	0.60 (0.55 to 0.65)